R & B Medical Group, INC.

R & B Medical Group, INC. was paid $15.42M by Medicaid between Jan 2018 and Dec 2023, across 186 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 42% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#56 of 561

Median peer was paid$222K

This provider vs. median69×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	210,051	$3.17M
2019	188,103	$2.82M
2020	149,179	$3.21M
2021	114,763	$3.15M
2022	71,692	$2.93M
2023	3,509	$154K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	42%	107,236	77,543	$6.50M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	4.1%	19,444	18,654	$629K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	4.1%	19,503	18,589	$629K
84443	Thyroid stimulating hormone (TSH)	3.6%	37,649	36,339	$553K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.4%	23,777	22,859	$523K
80061	Lipid panel	2.7%	37,882	36,919	$413K
80053	Comprehensive metabolic panel	2.6%	44,955	43,335	$404K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.4%	38,512	27,708	$363K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.2%	21,314	14,213	$338K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.1%	48,086	46,070	$321K
83036	Hemoglobin; glycosylated (A1C)	1.6%	30,173	29,024	$253K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.6%	2,397	2,376	$247K

174 more codes

80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.5%	4,125	$229K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.5%	11,388	$227K
86003		1.4%	1,631	$220K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.1%	5,277	$172K
87481		<1%	4,664	$149K
84439		<1%	19,253	$148K
87536		<1%	1,726	$140K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	4,011	$136K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	754	$131K
86480		<1%	2,196	$127K
88142		<1%	5,704	$110K
80074		<1%	2,381	$100K
84481		<1%	6,238	$97K
86803		<1%	6,183	$82K
87086	Culture, bacterial; quantitative colony count, urine	<1%	11,872	$81K
88174		<1%	4,214	$77K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	4,683	$77K
87186		<1%	4,422	$69K
83013		<1%	1,047	$67K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	850	$63K
82274		<1%	3,979	$61K
82607		<1%	4,827	$61K
86235		<1%	701	$59K
86696		<1%	2,876	$55K
87340		<1%	5,708	$53K
86592		<1%	13,214	$50K
87077		<1%	6,602	$46K
84403		<1%	1,857	$46K
82746		<1%	3,589	$45K
84153		<1%	2,914	$44K
86762		<1%	3,561	$44K
87088		<1%	8,086	$44K
83540		<1%	6,831	$42K
82043		<1%	8,171	$39K
82728		<1%	3,238	$39K
82570		<1%	8,728	$37K
86706		<1%	3,776	$37K
84480		<1%	2,849	$35K
86708		<1%	2,968	$33K
87070		<1%	3,876	$32K
86695		<1%	2,467	$32K
87522	Neg quan hep c or qual rna	<1%	764	$28K
88112		<1%	729	$28K
81001		<1%	8,135	$24K
86709		<1%	2,087	$22K
86787		<1%	1,828	$22K
84146		<1%	1,139	$21K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	621	$20K
83001		<1%	1,122	$20K
82785		<1%	1,250	$19K
83970		<1%	586	$18K
81003		<1%	10,532	$18K
86140		<1%	3,831	$17K
87511		<1%	610	$17K
83002		<1%	972	$17K
83655		<1%	1,386	$17K
88307		<1%	92	$15K
86481		<1%	217	$14K
86038		<1%	1,401	$14K
83550		<1%	2,115	$14K
82627		<1%	634	$14K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	286	$13K
84436		<1%	1,989	$12K
86780		<1%	1,153	$12K
80055		<1%	374	$12K
83735		<1%	1,969	$12K
84702		<1%	924	$11K
82951		<1%	883	$11K
87147		<1%	2,469	$11K
86850		<1%	3,328	$11K
84270		<1%	542	$10K
80076		<1%	1,428	$10K
82670		<1%	380	$10K
85652		<1%	4,136	$10K
87209		<1%	549	$9K
80048	Basic metabolic panel (calcium, ionized)	<1%	1,351	$8K
86704		<1%	691	$8K
87510		<1%	385	$8K
87480		<1%	385	$8K
85730		<1%	1,382	$8K
83690		<1%	1,171	$8K
83516		<1%	710	$7K
85610		<1%	1,977	$7K
86900		<1%	2,738	$7K
86376		<1%	513	$7K
86769		<1%	187	$7K
86431		<1%	1,193	$6K
80069		<1%	916	$6K
80305		<1%	553	$6K
84402		<1%	210	$5K
86694		<1%	370	$5K
84154		<1%	382	$5K
86677		<1%	361	$5K
87045		<1%	596	$5K
87177		<1%	548	$5K
85045		<1%	1,360	$5K
87338		<1%	348	$5K
86255		<1%	393	$4K
82950		<1%	1,082	$4K
84550		<1%	1,308	$4K
86141		<1%	453	$4K
82150		<1%	716	$4K
88342		<1%	78	$4K
84460		<1%	854	$4K
83880		<1%	172	$4K
84466		<1%	316	$4K
86705		<1%	338	$4K
88304		<1%	93	$4K
82947		<1%	1,181	$4K
84450		<1%	754	$4K
86225		<1%	317	$4K
81002		<1%	1,683	$4K
87150		<1%	119	$3K
86635		<1%	267	$3K
85060		<1%	246	$3K
82085		<1%	321	$3K
88312		<1%	79	$3K
86901		<1%	1,049	$3K
87184		<1%	354	$3K
86160		<1%	130	$3K
86200		<1%	437	$3K
83021		<1%	153	$3K
82550		<1%	546	$2K
82784		<1%	390	$2K
88160		<1%	123	$2K
87205		<1%	514	$2K
86735		<1%	177	$2K
82553		<1%	191	$2K
82977		<1%	271	$2K
84144		<1%	89	$2K
86765		<1%	133	$2K
36415	Collection of venous blood by venipuncture	<1%	3,567	$2K
87324		<1%	189	$2K
86800		<1%	120	$2K
84425		<1%	70	$1K
87081		<1%	204	$1K
85018		<1%	513	$1K
81000		<1%	386	$1K
86430		<1%	261	$1K
82270		<1%	362	$1K
84156		<1%	346	$1K
83721		<1%	115	$995.46
88141		<1%	91	$863.52
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	231	$836.29
86308		<1%	151	$794.95
85014		<1%	304	$739.20
88311		<1%	79	$703.10
81015		<1%	318	$690.93
84100		<1%	159	$653.55
83615		<1%	128	$639.26
86664		<1%	49	$590.68
87046		<1%	238	$570.26
82652		<1%	14	$507.36
84479		<1%	122	$476.90
86665		<1%	16	$441.44
85660		<1%	92	$426.69
82533		<1%	27	$418.60
86360		<1%	16	$409.20
83525		<1%	34	$395.15
84207		<1%	12	$367.08
82310		<1%	116	$352.03
89055		<1%	92	$342.40
86359		<1%	16	$328.56
82272		<1%	111	$255.30
84681		<1%	12	$239.52
82105		<1%	13	$156.39
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	<1%	18	$138.64
83718		<1%	13	$106.92
86593		<1%	27	$104.40
82465		<1%	25	$91.10
85651		<1%	114	$77.68
86060		<1%	14	$73.64
81025		<1%	14	$35.70
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	0%	18	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBUSHERI, SHIELA (CEO)